Last Updated: 18 Jul 2025
Source: Statifacts
Solid Tumors Market (By Indication: Neuroblastoma, Glioblastoma, Breast Cancer, Pancreatic Cancer, Ovarian Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Others; Industry Size, Share, Growth, Trends 2025 to 2034
The US solid tumors market size was evaluated at USD 224 million in 2024 and is expected to grow around USD 6,323 million by 2034, registering a CAGR of 45.18% from 2025 to 2034. The market is on the verge of rising constantly. This growth is mainly attributed to the surging number of cases and the research being done. The biotechnology companies are investing in the formulation of therapies and treatments, contributing to the further rise of the market.
| Industry Worth | Details |
| Market Size in 2025 | USD 224 Million |
| Market Size by 2034 | USD 6,323 Million |
| Market Growth Rate from 2025 to 2034 | CAGR of 45.18% |
The U.S. Solid Tumors market talks about solid tumors, which are abnormal masses of tissue that are an outcome of the unrestrained growth of cells. They generally do not comprise cysts or liquid areas and chiefly affect the blood and bone marrow. Their major categories are benign (non-cancerous) or malignant (cancerous). Some of the examples of tumors include carcinomas (cancers of epithelial cells), sarcomas (cancers of connective tissues), lymphomas (cancers of the lymphatic system), and brain tumors.
Since the advent of technologies is leading to groundbreaking therapy development and treatment procedures, and the larger investment in developing drugs and other medications is contributing to market growth. The US has seen a substantial regression in the death rates triggered by cancer.
The U.S. Solid Tumors market has benefited largely from AI. Its features, including quicker, precise, and efficient working processes, have helped the healthcare sector immensely. AI uses algorithms to study medical images, including CT scans and MRIs, which results in initial tumor detection. AI can analyze digital images related to pathology for the identification of cancer cells and examine tumor traits efficiently. AI can not only help radiologists plan radiation treatment programs automatically, but also assist surgeons in getting detailed insights about tumor characteristics while expecting results of the surgery in a more well-planned and organized structure.
The U.S. Solid Tumors market is driven by the rising number of cancer cases and increasing research and development done in this field. Cancer is one disease that is affecting millions of people's lives yearly. These cases involve a considerable portion of breast, prostate, ovarian, colorectal, and other cancers. For treating these conditions, dedicated testing and treatment strategies are required. That is when technologies like liquid biopsies and genetic profiling help by improving the proficiency of solid tumor testing. Diagnostic tools that can identify tumors beforehand are in demand, as the early detection is being underscored as well.
The pharmaceutical companies are greatly investing in research and development for solid tumor therapies. The production of new medicines and treatment ways is thus growing. Having said that, immunotherapies have seen groundbreaking success in treating some solid tumors, leading to more research in the field. The research and development are increasingly funded by the government, and it is supporting drug development. Additionally, contract research organizations (CROs) are taking a deeper dive into solid tumors by offering specific services and expertise.
The U.S. Solid Tumors market presents a few challenges as well. These mainly include complicated manufacturing processes and hefty costs of production. Cellular immunotherapies comprise several steps, including cell isolation, activation, genetic modification, and more. All patients’ cells need a different therapy, and that too radically, which has an impact on the end quality of the product. Routing growing regulatory frameworks across different authorities causes difficulty in getting the therapies to the market.
For the production of any medicine or therapy, expensive reagents, single-use disposables, and specialized equipment are essential. Cell-based therapies repeatedly need dedicated, GMP-compliant facilities for production. A lot of products need scaling up, as there are several patients to cater to. This needs a considerable amount of investment and infrastructure. As a consequence of these factors, the manufacturing costs can be seen increasing, and the treatments becoming expensive while limiting the market growth.
What are the U.S. Solid Tumors Market Opportunities?
The U.S. Solid Tumors market creates opportunities for growth, some of which are the enhancement of diagnosis and remedial plans and integration of digital health technologies like telemedicine and AI-powered diagnostic tools. Digital health tools can analyze any patient’s data, including genomic information and medical history. This assists the doctors in formulating effective treatment plans for different patients. Digital technologies can be used in radiation therapy while lessening the damage caused to healthy tissue. The digital tools offer access to resources for dealing with their health and improving the chances of following the treatment plans more cautiously. Additionally, with the help of telemedicine and virtual consultation, specifically patients from remote areas or the ones with travel issues, can access health care quite easily.
While talking about cancer-related advances in development plans, both Duggan and Zanganeh said, “Rapidly developing novel mechanisms that go beyond what is currently available to patients and physicians is what we believe will make the most significant impact for those facing the greatest challenges from cancer today. As we seek to accelerate the development of our potentially transformative ivonescimab across non-small cell lung cancer and other solid tumor settings, this collaboration will allow us to quickly advance beyond our promising late-stage development plan to evaluate ivonescimab in combination with some of the most innovative ADCs from Pfizer.”
The U.S. Solid Tumors market is dominated by the breast cancer segment. The people in the US are becoming more aware of the symptoms of breast cancer. They now understand that it is vital to get a diagnosis early so that the disease can be detected in the initial phase. Due to this, more women are paying visits to the doctors as they notice even subtle changes in their bodies. Screening methods like ultrasound enable quicker identification of tumors, even before they are demonstrable. Moreover, technologies like 3D mammography, contrast-enhanced mammography, and MRI allow more precise detection of breast cancer.
The prostate cancer segment is the fastest-growing one in the market. The researchers are more into exploring and developing new treatments and medications with fewer complications. This is because the current treatments given for prostate cancer may have side effects such as sexual dysfunction, urinary incontinence, and bowel problems. It is extremely necessary to understand the molecular mechanisms triggering prostate cancer. The uncovering of genetic mutations and other molecular alterations that give rise to the development of disease is possible due to extensive research. In addition, using diagnostic tools that can distinguish between indolent and aggressive cancers is important for accurate diagnosis. Advanced imaging and biomarker tests help with this tremendously as they offer more details of the tumor and its characteristics.
The ovarian cancer segment can be seen growing notably in the U.S. Solid Tumors market. The indications of ovarian cancer like, bloating, pelvic pain, and changes in bowel habits, in the initial stages, can often be unclear and these can be misunderstood to be some other conditions that are less serious. Also, as ovarian tumors grow slowly, their physical examination becomes problematic, leading to a delay in diagnosis. Therapies designed to diagnose and treat these tumors come into play and help with the treatment. Immunotherapies are becoming a popular choice as they can improve the body's immune system in fighting ovarian cancer. Moreover, drugs like PARP inhibitors have proven to be effective in treating this type of cancer, predominantly in cases with BRCA mutations.
The colorectal cancer segment is growing at a quicker pace in the market. This cancer type is common among the elderly. An increase in cases with young individuals can be seen, though, especially among those aged 20-39. As a result, understanding colorectal cancer and developing treatments is a must. The pharmaceutical companies are largely investing in the research and development of new CRC treatments. The creation of new ways, like nanotechnology-based drug delivery systems and logic-gated CAR-T cell therapies, is resulting in the expansion of the range of treatment choices, driving the market further.
Which recent developments took place in the U.S. Solid Tumors market? In January 2025, Ginkgo Bioworks publicized a research association with Universal Cells for enhancing next-generation induced pluripotent stem cell (iPSC)-derived cancer cell therapies. In February 2025, Summit Therapeutics Inc. revealed a clinical trial collaboration with Pfizer Inc. for the evaluation of ivonescimab, which is a new and investigational PD-1 / VEGF bispecific antibody, together with numerous Pfizer’s antibody drug conjugates (ADCs) throughout assorted solid tumor settings.
The U.S. Solid Tumors market is highly competitive, with leading pharmaceutical companies such as Pfizer, Roche, Bristol Myers Squibb, Novartis, AstraZeneca, Merck, Amgen, Eli Lilly, Johnson & Johnson, Moderna, and BioNTech holding the highest market share. Emerging biotech firms also play a crucial role by fostering a dynamic and evolving competitive landscape.
The market is dominated by several pharmaceutical companies renowned for their significant contributions to cancer research and treatment. Based on recent data, the top three leading companies are:
Pfizer Inc. is a research-based biopharmaceutical company. Its products attend to a wide variety of remedial areas like anti-infectives, oncology, cardiovascular, diabetes, obesity, inflammation, immunology, rare diseases, and bacterial infections. Healthcare providers, hospitals, clinics, and pharmacies use the company's products for the treatment of diverse medical conditions. The company operates in manufacturing units located in Belgium, Germany, India, Ireland, Italy, Japan, Singapore, the US, including others.
The yearly revenue of Pfizer Inc. was positioned at $63,627,000 in 2024.
Roche, which is a subsidiary of Roche Holding AG, is a supplier of in vitro diagnostics as well as a trader of transformative innovative solutions in key disease areas. It offers medicines for the treatment of cancer, other autoimmune diseases, central nervous system disorders, ophthalmological disorders, and infectious diseases. The company handles research for the identification of new methods to prevent, diagnose, and treat diseases. It provides its products and services to hospitals, healthcare professionals, commercial laboratories, researchers, and pharmacists.
The yearly revenue of Roche was accounted to be $62,395,000 in 2024.
Bristol Myers Squibb Co. (BMS) is a biopharmaceutical company. It is involved in the development, licensing, production, promotion, circulation, and sale of modern biopharmaceutical products. It deals its products in therapy areas such as oncology,
hematology, immunology, cardiovascular, and neuroscience. It also deals in co-development, co-commercialization, licensing, or joint venture arrangements with third parties. The company delivers its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. It has manufacturing units in the US, Switzerland, Puerto Rico, Ireland, and the Netherlands.
The yearly revenue of Bristol Myers Squibb stood at $48,300,000 in 2024.
| Segments | Shares (%) |
| Neuroblastoma | 6% |
| Glioblastoma | 9% |
| Breast Cancer | 18% |
| Pancreatic Cancer | 8% |
| Ovarian Cancer | 10% |
| Lung Cancer | 22% |
| Prostate Cancer | 11% |
| Colorectal Cancer | 12% |
| Others | 4% |
